The expression of somatostatin receptors 1 and 2 in benign, pre-malignant and malignant laryngeal lesions

Nicholas D. Stafford, L. T. Condon, M. J C Rogers, A. W. Macdonald, Stephen Atkin

Research output: Contribution to journalArticle

8 Citations (Scopus)


The role of chemotherapy in squamous cell carcinoma of the larynx has not been clearly defined. Whilst toxic chemotherapy regimes may confer a marginal improvement in survival, surgery and radiotherapy remain the mainstay of treatment. Somatostatin is a naturally occurring peptide, which exerts antiproliferative and antiangiogenic effects via five membrane-bound receptor subtypes. The expression of somatostatin receptor subtypes (SSTRs) 1 and 2 was studied in benign, pre-malignant and malignant laryngeal specimens. Epithelial expression of SSTR1 was detected in 4/6 (67%) Reinke's oedema, 5/6 (83%) pre-malignant and 8/12 (67%) malignant specimens, with virtually no stromal or vascular expression. High levels of epithelial SSTR2 expression were noted in all Reinke's oedema specimens, compared with low-to-moderate levels in only 2/6 (33%) pre-malignant and 3/12 (25%) malignant specimens (P < 0.01). This 'loss' of epithelial SSTR2 expression may provide a growth advantage in pre-malignant and malignant laryngeal lesions. Vascular expression of SSTR2 was ubiquitous in all groups, with scant stromal expression. Overall, most (>80%) pre-malignant and malignant laryngeal specimens expressed at least one of the two SSTR subtypes studied. Somatostatin analogues may have a therapeutic role in squamous cell carcinoma of the larynx.

Original languageEnglish
Pages (from-to)314-319
Number of pages6
JournalClinical Otolaryngology and Allied Sciences
Issue number4
Publication statusPublished - Aug 2003
Externally publishedYes



  • Immunohistochemistry
  • Larynx pre-malignant
  • Reinke's oedema
  • Somatostatin
  • Somatostatin receptors
  • Squamous cell carcinoma
  • SRIF (somatotroph release inhibiting factor)

ASJC Scopus subject areas

  • Otorhinolaryngology

Cite this